Modified-Release Budesonide Composition for IgA Nephropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IgA nephropathy, a progressive autoimmune kidney disease, are inadequate and often lead to significant side effects, with no approved therapies directly addressing the underlying cause, and existing immunosuppressive agents have undesired systemic side effects.
Innovation Solution
A budesonide formulation with a specific in vitro release profile is administered locally to the distal ileum, targeting the site of IgA production, reducing galactose-deficient IgA antibodies and minimizing systemic exposure to minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic immunosuppressive agents are used to treat IgA nephropathy, then disease progression is slowed, but significant systemic side effects occur
Solution Approach 1:
The invention divides the treatment approach by segmenting the release of budesonide into two distinct phases: an initial rapid release phase (0-4 hours) providing high local concentration at the ileum, followed by a sustained release phase (4-24 hours) maintaining therapeutic levels. This segmentation allows effective local treatment while minimizing systemic exposure and side effects.
Solution Approach 2:
The formulation achieves local quality by concentrating budesonide delivery at the specific anatomical site of IgA production (distal ileum/Peyer's patches) through targeted rapid release, while the sustained release phase maintains local therapeutic levels without requiring systemic distribution. This localized action reduces harmful systemic effects while maintaining treatment efficacy.
2Object-affected harmful factors
If antihypertensive medications are used to manage IgA nephropathy symptoms, then blood pressure and proteinuria are reduced, but the underlying cause is not addressed
Solution Approach 1:
The invention applies preliminary action by targeting the root cause of IgA nephropathy (aberrant IgA production in Peyer's patches) before disease progression occurs. By delivering budesonide directly to the site of pathogenic IgA production, the formulation prevents the formation of immune complexes and subsequent kidney damage, rather than merely managing symptoms after they manifest.
Solution Approach 2:
Budesonide serves as an intermediary agent that specifically targets and modulates the immune response at the source of pathogenic IgA production. The formulation mediates between the immune system's IgA production and the kidney, preventing the harmful cascade that leads to nephropathy while avoiding the need for broad-spectrum immunosuppression.
3Quantity of substance
If high doses of systemic corticosteroids are administered, then proteinuria is reduced, but adverse events such as high blood pressure, weight gain, diabetes, serious infections and osteoporosis occur
Solution Approach 1:
The invention extracts the therapeutic benefit of corticosteroid treatment (reduction of proteinuria and immune complex formation) while removing the harmful systemic effects. By formulating budesonide for targeted rapid release at the ileum followed by sustained local release, the treatment achieves effective proteinuria reduction without the systemic adverse events associated with high-dose corticosteroids.
Solution Approach 2:
The formulation uses a short-acting, rapidly cleared budesonide delivery system that provides intense local therapy during the critical early period (0-4 hours) and maintains sustained levels (4-24 hours), then is completely eliminated without accumulating to cause systemic side effects. This disposable-like approach to drug delivery achieves therapeutic goals without long-term harmful effects.
Data Source
AI summary
The present invention provides for a method of treatment of IgA nephropathy, which method comprises:(i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test;(a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.2;(b) the composition fulfils the requirement that no more than about 10% of the budesonide is released into a pharmaceutically-relevant dissolution medium within about 30 minutes; and(c) the composition fulfils the requirement that at least about 70% of the budesonide is released into the pharmaceutically-relevant dissolution medium within about 120 minutes;(ii) wherein the method comprises the step of administering said composition to a patient with IgA nephropathy in need of said treatment.